Analysis of Vaccinal Process Peculiarities in Persons Immunized with Smallpox Live Vaccine in Case of Primary Vaccination and Revaccination

Immunization against smallpox may be attended by serious complications. The premises for the differences in postvaccinal reaction intensity are underexplored. In this paper presented is the review of peculiarities of postvaccinal manifestations in members of the Russian population primarily immunized against smallpox as compared to the revaccinated ones. Examined has been the cohort of 217 people, of whom 82 are vaccinated initially, and 135 - repeatedly within the period from 2000 to 2013. Average age of the vaccinated is 40.0 years (ranged 20 to 40). Studied has been severity of vaccine-challenged condition and cutaneous inflammatory vaccinal elements. In case of initial vaccination medium severity has been observed 2.1 times oftener than low one. In case of revaccination - low level of severity has been registered 17.7 times more frequently than the medium one. Hyperemia zone is 2.2 times greater as regards primary vaccination compared to revaccination, zone of induration - 1.9 times. The diameter of the sore is 1.3 and its shedding time is 1.4 times greater and longer, respectively. Thus, initial vaccination follows more severe course and is attended by expressed response in comparison to booster one.

вакцинация, натуральная оспа, клинические признаки, накожная вакцинация, вакцинальные реакции, vaccination, smallpox, clinical signs, supracutaneous vaccination, vaccinal reactions

1. Ladny I.D. [Smallpox Eradication and Prevention of Its Reemergence]. M.: Meditsina; 1985. 230 p.

2. Marennikova S.S. [To the 30th anniversary of smallpox eradication worldwide]. Zh. Mikrobiol. Epidemiol. Immunobiol. 2011; 3:121–4.

3. [Scientific review of variola virus research, 1999–2010]. WHO. 2011.

4. Onishchenko G.G., Drozdov I.G., editors [30 Years after Smallpox Eradication: Investigations Continue]. Novosibirsk; 2010. 283 p.

5. Shchelkunov S.N. [Penetration of orthopoxviruses to the protective systems of mammalian organism]. Mol. Biol. 2011; 45(1):30–43.

6. Biagini Ph., Thиves C., Balaresque P.. Graut A, Cannet C., Keyser C., Nikolaeva D., Crubzy E., Alekseev А. Variola Virus in a 300-Year-Old Siberian Mummy. J. Med. 2012; 367:2057–9.

7. Elizaga M.L., Vasan S., Marovich M.A., Sato A.H., Lawrence D.N., Chaitman B.R., Frey S.E., Keefer M.C. Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review. PLoS One. 2013; 8:1–8.

8. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox Vaccination: A Review, Part I. Background, Vaccination Technique, Normal Downloaded from Vaccination and Revaccination, and Expected Normal Reactions. Clin. Infect. Dis. 2003; 37:241–50.

9. Keckler M.S., Reynolds M.G., Damon I.K., Kalem K.L. The effects of post-exposure smallpox vaccination on clinical disease presentation: Addressing the data gaps between historical epidemiology and modern surrogate model data. Vaccine. 2013; 31(45):5192–201.

10. Nak-Hyun Kima, Yu Min Kanga, Gayeon Kima, Pyoeng Gyun Choea, Jin Su Songa,Kwang Hee Leeb, Baik-Lin Seongb, Wan Beom Parka, Nam Joong Kima,Myoung-don Oha. An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults. Vaccine. 2013; 31:5239–42.

11. Ovsyannikova I.G., Poland G.A. Vaccinomics: Current Findings, Challenges and Novel Approaches for Vaccine Development. AAPS J. 2011; 13 (3):438–45.

12. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 2004; 350:342–50.

13. Von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., Handley A., Mateo L., Siersbol H., Kollaritsch H., Chaplin P. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010; 28(5):1209–16.